A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128 · DeLLphi-312 Phase 3Active, not recruiting
- Lead sponsor
- Amgen (Industry)
- Enrollment
- 350 (actual)
- Start date
- 18 Aug 2025
- Primary completion
- 4 Jan 2029 (estimated)
- Study completion
- 15 Aug 2029
- Last update posted
- 8 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- Tarlatamab Drug
- Durvalumab Drug
- Carboplatin Drug
- Etoposide Drug
Conditions and primary outcome
- Small-cell Lung Cancer
- Extensive Stage Small-cell Lung Cancer
Primary outcome
Overall Survival (OS) (Up to approximately 3.5 years); Progression free survival (PFS) (Blinded Independent Central Review [BICR] Assessed) (Up to approximately 3.5 years)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07005128.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07005128 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.